<DOC>
	<DOCNO>NCT02191098</DOCNO>
	<brief_summary>To assess safety tolerability ALT-803 , well , potential efficacy ALT-803 HIV</brief_summary>
	<brief_title>Proof Principle Study Pulse Dosing IL-15 Deplete Reservoir HIV Infected People</brief_title>
	<detailed_description>This open-label , single-arm intra-patient dose escalate pilot study ALT-803 , recombinant human super agonist interleukin-15 ( IL-15 ) complex expansion cohort maximum tolerate dose ( MTD ) . The primary aim investigate safety tolerability ALT-803 HIV-infected people receive potent optimized antiretroviral therapy . All infusion occur Monday . Subjects monitor 24 hour first infusion 6 hour subsequent infusion , provide unacceptable toxicity .</detailed_description>
	<criteria>1 . HIV1 infect adult age 18 year . 2 . Stable ART least 36 month 3 . Screening plasma HIV RNA level level quantification ( &lt; 40 &lt; 50 copy RNA/mL depend assay ) ≥ 2 year ( single measurement level detection &lt; 100200 copies/ml allow ) 4 . Screening CD4 count ≥500 cells/mm3 5 . Laboratory test perform within 14 day study enrollment : 1 . WBC ≥ 3000/mm3 2 . Platelets ≥ 50,000/mm3 [ Patients may transfuse meet requirement ] 3 . Hemoglobin ≥ 8 g/dL ( &gt; 80g/L ) [ Patients may transfuse meet requirement ] 4 . Calculated glomerular filtration rate ( GFR ) &gt; 45 mL/min/1.73m2 5 . Total bilirubin ≤ 2.0 X upper limit institutional normal ( ULN ) 6 . AST , ALT , ALP ≤ 2.0 X ULN 6 . Adequate pulmonary function without clinical sign severe pulmonary dysfunction . PFTs &gt; 50 % predict symptomatic prior know impairment . 7 . Ability prednisone immunosuppressive drug least 14 day first dose study drug 8 . Women child bear potential men partner child bear potential must agree use effective contraception therapy 4 month completion therapy 9 . Voluntary write consent 1 . Active infection HIV currently require systemic antimicrobial therapy 2 . Previously treat study receive previous ALT803 3 . Latent TB infection active TB disease prior complete standard regimen antiTB therapy 4 . Active fungal infection require systemic antifungal therapy 5 . Active recurrent herpes varicellazoster virus infection require treatment ( chronic suppression ) 6 . Chronic hepatitis B C 7 . Planning current pregnancy breastfeed 8 . Intended modification antiretroviral therapy next 24 week 9 . NYHA ( New York Heart Association ) Class III IV heart failure , uncontrollable supraventricular arrhythmia , history ventricular arrhythmia , clinical sign severe cardiac dysfunction 10 . Symptomatic congestive heart failure , unstable angina pectoris , Myocardial infarction within 6 month prior screen 11 . Marked baseline prolongation QT/QTc interval ( e.g . demonstration QTc interval great 500 millisecond ) 12 . History evidence uncontrollable CNS disease 13 . Prior organ allograft allogeneic transplantation 14 . Ongoing chronic systemic regular inhale corticosteroid use immunosuppressive therapy ( history mild asthma require therapy eligible ) 15 . Psychiatric illness/social situation would limit compliance study requirement 16 . Other illness opinion investigator would exclude patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>ART</keyword>
</DOC>